National Cancer Centre Singapore

What National Cancer Centre Singapore does

National Cancer Centre Singapore (NCCS), founded in 1999 and operating as a not-for-profit specialty centre under SingHealth, is Singapore's national referral institution for complex cancer care. The centre delivers multidisciplinary oncology services spanning medical oncology, radiation oncology, surgical oncology, oncologic imaging, and supportive and palliative care. It operates from a 24-storey integrated facility at 30 Hospital Boulevard and extends reach through satellite clinics at Changi General Hospital and Sengkang General Hospital, an established GP referral network, and a Patient Liaison Service for international and non-resident patients. NCCS manages the majority of cancer cases within Singapore's public healthcare sector.

NCCS operates Singapore's only public proton beam therapy facility at the Goh Cheng Liang Proton Therapy Centre, supported by a SGD 50 million Goh Foundation gift, with 4 treatment gantries and 500+ patients treated since June 2023. The centre is also the only institution in Southeast Asia conducting the HALT histotripsy clinical trial for liver tumours on Asian patient anatomy, funded by a SGD 12 million commitment from Li Ka Shing Foundation and Temasek Trust. Other notable clinical and research programmes include the SOLSTICE lung cancer screening study, a VR-based paediatric preparation tool developed with Nanyang Polytechnic, cancer genetics services, psychosocial oncology, and a Clinical Trial Pharmacy managing over 150 trials.

The business model is anchored in clinical services revenue claimable through MediShield Life, MediSave, and private insurance, with ancillary streams from medical report fees (SGD 12-222 per request) and sponsored clinical trials. Pricing signals include proton therapy at SGD 40,000-53,000 per course and MCED tests at SGD 1,000-5,000 each. NCCS participates in Singapore's National Precision Medicine Programme (targeting 450,000 genomes), the RISE research institute with NTU Lee Kong Chian School of Medicine, and active collaborations with Lucence, DxD Hub, GE Healthcare, and the Ministry of Health on AI-powered profiling, multiomic assays, and Healthier SG preventive care initiatives. As a government-linked institution, NCCS is funded through a combination of government budget allocations, philanthropic grants, clinical service revenue, and sponsored research.

Name

National Cancer Centre Singapore

Legal name

National Cancer Centre of Singapore Pte Ltd

Website

https://nccs.com.sg

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

National Cancer Centre Singapore is Singapore's national specialty centre for complex cancer care, providing multidisciplinary oncology services including the country's only public proton therapy facility. Operating under SingHealth, NCCS serves cancer patients through treatment, research, and education, with active clinical trials in histotripsy, MCED, and precision oncology.

Ownership category

akta.pro rank

Product category

Cancer Treatment Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Diagnostic Imaging Centers (621512), General Medical and Surgical Hospitals (622110)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Surgical Oncology (HLAKAFAG)

Keywords

• Oncology treatment services
• Radiation oncology
• Proton beam therapy
• Cancer screening services
• Clinical research trials

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Clinical Services: Revenue generated from outpatient consultations, diagnostic procedures, chemotherapy, radiation therapy, proton therapy, and inpatient cancer treatments. Services are claimable through MediShield Life, MediSave, and private insurance.
2. Medical Reports: Fees charged for medical reports, insurance form completion, and certified true copies. Standard fees ranging from $12 to $222 depending on report complexity.
3. Clinical Trials: Conduct of pharmaceutical-sponsored and investigator-initiated clinical trials. Clinical Trial Pharmacy manages over 150 trials.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

National Cancer Centre Singapore (NCCS) is Singapore's national specialty centre for complex cancer care, providing integrated multi-disciplinary cancer treatment across medical oncology, radiation oncology, surgical oncology, oncologic imaging, supportive and palliative care, and clinical trials. NCCS operates the Goh Cheng Liang Proton Therapy Centre, the only public proton beam therapy facility in Singapore, and extends care through satellite clinics at Changi General Hospital and Sengkang General Hospital. The centre leads Asian-focused clinical research including the HALT histotripsy liver tumour trial, multi-cancer early detection studies, AI-powered genomic profiling, and VR-based pediatric preparation tools.

Product overview

National Cancer Centre Singapore (NCCS) is Singapore's national specialty centre for complex cancer care, operating as a single integrated cancer centre offering comprehensive treatment, research, education, and support services. The centre provides a full spectrum of oncology services including Medical Oncology, Radiation Oncology, Surgery & Surgical Oncology, Oncologic Imaging, and Supportive & Palliative Care. NCCS operates the Goh Cheng Liang Proton Therapy Centre, the only public proton therapy facility in Singapore, alongside specialist centres for Cancer Genetics, Comprehensive Liver Cancer, and Lung Multidisciplinary Clinic. The centre extends its services through satellite clinics at Changi General Hospital and Sengkang General Hospital. NCCS also leads clinical research initiatives including clinical trials, cancer screening programmes (lung, prostate), and precision medicine studies using AI and genomic technologies.

Differentiator

Problem solved

Functional benefit

Brands

• Goh Cheng Liang Proton Therapy Centre: The proton therapy centre at NCCS offering advanced radiation treatment using proton beam technology to precisely target and destroy cancer cells while minimising damage to surrounding healthy tissues.

Products and services

• Medical Oncology Comprehensive cancer treatment using chemotherapy, immunotherapy, and targeted drug therapies administered by oncology specialists for patients with solid tumours and haematologic cancers.
• Radiation Oncology Advanced radiation therapy treatments including IMRT, stereotactic radiosurgery, and other modalities for precise cancer cell destruction. Includes the pediatric VR preparation tool launched in 2026 in partnership with Nanyang Polytechnic.
• Goh Cheng Liang Proton Therapy Centre The only public healthcare facility in Singapore offering proton beam therapy, an advanced radiation treatment that precisely targets and destroys cancer cells while minimising damage to surrounding healthy tissues, especially beneficial for paediatric and complex cancers.
• Surgery & Surgical Oncology Surgical procedures for cancer treatment including minimally invasive and robotic-assisted surgeries performed by surgical oncology specialists across tumour types.
• Oncologic Imaging Advanced diagnostic imaging services including CT, MRI, PET scans, and interventional radiology for accurate cancer diagnosis, staging, and treatment planning.
• Supportive & Palliative Care Specialised care focusing on symptom management, pain relief, and quality of life improvement for cancer patients at any stage of illness.
• Cancer Genetics Service Genetic testing and counselling services for hereditary cancer syndromes including BRCA testing, Lynch syndrome evaluation, and family risk assessment.
• Comprehensive Liver Cancer Clinic Multidisciplinary clinic providing specialised diagnosis, treatment, and management of liver cancers including access to clinical trials such as the HALT histotripsy trial.
• Pharmacy Services Comprehensive pharmacy services including outpatient oncology pharmacy, ATU pharmacy, clinical trial pharmacy managing over 150 trials, medication delivery service, and chemotherapy counselling.
• Lung Cancer Screening Low-dose CT screening services for high-risk individuals including the SOLSTICE research study for smokers and non-smokers with family history of lung cancer.
• Prostate Cancer Screening PSA testing and clinical assessment services for early detection of prostate cancer with support for active surveillance of low-risk cases.
• NCCS Oncology @ CGH Oncology services delivered at Changi General Hospital providing convenient access to NCCS cancer care specialists for eastern Singapore patients.
• NCCS Oncology @ SKH Oncology services delivered at Sengkang General Hospital providing convenient access to NCCS cancer care specialists for northeastern Singapore patients.
• Psychosocial Oncology Emotional support, financial aid, and practical assistance services for cancer patients and their families including support groups, patient programmes, and survivorship resources.
• Clinical Trials Access to innovative cancer treatments through clinical trials including histotripsy, MCED tests, multiomic profiling assays, and novel therapeutic approaches. The Clinical Trial Pharmacy manages over 150 trials.
• Geriatric Oncology Specialised cancer care for elderly patients addressing age-related health considerations, treatment tolerability, and geriatric assessment.
• Haematology Diagnosis and treatment of blood cancers including leukaemia, lymphoma, and myeloma.
• Lung Multidisciplinary Clinic Coordinated care for lung cancer patients involving multiple specialists for comprehensive treatment planning.

Quantifiable outcome

• Over 500 patients treated with proton therapy since June 2023, including 37 pediatric patients
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature5 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Nanyang PolytechnicminorStrategic or Co-development PartnerDesign and media students developed VR simulations in partnership with NCCS to help young cancer patients prepare for CT scans and radiotherapy, reducing anxiety and reliance on general anaesthesia.
• Nanyang Technological University (NTU) Lee Kong Chian School of MedicinecoreStrategic or Co-development PartnerJoint establishment of RISE institute to address cancer prevention and early detection gaps in Asia, launching studies for MCED blood tests targeting Asian populations underrepresented in Western clinical data.
• National Taiwan University HospitalminorStrategic or Co-development PartnerPartnership for MELODY study evaluating tumor-informed MRD approaches in sarcoma patients, part of multinational clinical research collaboration.
• Ministry of Health SingaporecoreOthersGovernment partnership for national clinical studies on MCED tests and alignment with Healthier SG preventive care initiative, including SG$2.5 billion RIE 2030 Plan investment.
• National University Cancer Institute, SingaporecoreStrategic or Co-development PartnerJoint development of sarcoma care guidance including clinical handbook 'Clinical Management of Bone and Soft Tissue Tumours' with 70 local and international contributors across specialties.
• Singapore General HospitalcoreStrategic or Co-development PartnerCollaboration on HALT histotripsy trial for liver cancer treatment, with shared expertise in hepato-pancreato-biliary surgery and interventional oncology.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• MD Anderson Cancer Center: World-leading comprehensive cancer center with integrated medical, radiation, and surgical oncology plus robust clinical research. Comparable to NCCS as a national specialty cancer hospital delivering multi-disciplinary care and pioneering advanced therapies, though operating at materially larger scale in the US.
• Memorial Sloan Kettering Cancer Center: Premier US cancer hospital combining patient care, research, and education across all oncology subspecialties. Directly comparable to NCCS's integrated model — medical/radiation/surgical oncology plus clinical trials and supportive care under a single institutional umbrella.
• European Institute of Oncology (IEO): Italian comprehensive cancer center integrating medical, radiation, and surgical oncology with a strong research focus and proton therapy capability. Comparable to NCCS in delivering advanced radiation modalities within an integrated academic oncology model.

Direct peers

• National Cancer Center Japan: Japan's national specialty cancer center offering medical oncology, radiation oncology, surgery, and clinical trials. The closest direct national-level peer to NCCS in terms of mandate, scope of services, and government-affiliated operating model in an Asian market.
• Peter MacCallum Cancer Centre: Australia's flagship public cancer hospital and research center, delivering integrated multi-disciplinary oncology with a strong proton therapy and clinical trials portfolio. Highly comparable to NCCS in scope, public-affiliation, and translational research focus in the Asia-Pacific region.
• Seoul National University Cancer Hospital: Korea's leading public academic cancer hospital providing comprehensive medical, radiation, and surgical oncology plus active clinical trials. Comparable to NCCS as a national-referral cancer center in a developed Asian market with similar technology adoption patterns.
• National University Cancer Institute, Singapore (NCIS): Singapore's other public-sector comprehensive cancer center, operated under the National University Health System. The most direct domestic competitor to NCCS, jointly collaborating on histotripsy and sarcoma care but competing for the same patient pool and referring physicians.
• Tata Memorial Hospital: India's national tertiary cancer center providing comprehensive oncology care with high patient volumes and active clinical research. Comparable to NCCS in mission (national public cancer center), multi-disciplinary scope, and clinical trial activity, though at very different scale and reimbursement context.

Others

• Duke-NUS Medical School (Cancer & Stem Cell Biology Program): Singapore-based academic research partner conducting translational oncology and precision medicine work that complements NCCS's clinical mission. Relevant as a domestic research/education collaborator rather than a treatment competitor.

Emerging players

• Icon Group: Australia-headquartered private oncology provider rapidly expanding across Asia-Pacific with medical oncology, radiation therapy, and day oncology services. Comparable to NCCS in oncology service delivery, but operating under a private-pay model in geographies where NCCS draws international patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/NCCSonline
• Facebookfacebook.com/NationalCancerCentreSingapore
• LinkedInlinkedin.com/company/nationalcancercentresingapore
• Instagraminstagram.com/nationalcancercentresg

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Cancer Centre Singapore